Information Provided By: 
Fly News Breaks for March 28, 2019
MDCO
Mar 28, 2019 | 09:04 EDT
Baird analyst Madhu Kumar initiated The Medicines Co with an Outperform rating and $80 price target. In a research note to investors, Kumar contends that PCSK RNAi drug inclisiran has the potential to disrupt cardiovascular disease driven by hypercholesterolemia, with top-line results from the company's Phase 3 ORION-9/10/11 trials potentially serving as key positive catalysts for shares. The analyst expects top-line results for ORION-9/10/11 in the third quarter, saying he has been "impressed" by results from the Phase 2 ORION-1 trial.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
